Abstract
In the period from August 1991 to August 1994, the Dutch Slide Review Committee of Adult Leukemias classified 14 leukemias as AML-M0. We reviewed the clinical characteristics and response to therapy of these patients. Eight patients were male. Patients' age ranged from 7 to 77 years (medium age 62 years). There was a striking homogeneity in morphological appearance of the blasts, being small to medium-sized round cells with often an eccentric nucleus with fine chromatin, several distinct nucleoli, and a high nucleo-cytoplasmic ratio. In addition to myeloid-associated markers such as CD13 and CD33, the blasts of all patients were positive for CD34 and HLA-DR, pointing to their immature differentiation stage. TdT was present in the blasts of 71%, CD7 was positive in the blasts of 42% of the patients. No consistent cytogenetic abnormalities were found. With respect to the treatment outcome, four patients achieved a complete remission after remission-induction treatment. The median survival was 4.5 months. Our present study shows AML-M0 to be an immature leukemia, uniform in morphology and immunological phenotype, with no consistent cytogenetic phenotype and with a poor clinical outcome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bain BJ (1990) Acute leukaemia. In: Bain BJ (eds) Leukaemia diagnosis, a guide to the FAB classification. Gower Medical, London, pp 1–43
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:620–625
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1985) Criteria for the diagnosis of acute leukaemia of megakaryocyte lineage (M7). Ann Intern Med 103:460–462
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1991) Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 78:325–329
Boekhorst PAW te, Leeuw K de, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Löwenberg B, Sonneveld P (1993) Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 82:3157–3162
Campos L, Guyotat D, Arachimbaud E, Devaux Y, Treille D, Larosc A, Maupas J, Gentilhomme O, Ehrsam A, Fiere D (1989) Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol 72:161–166
Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D (1992) Clinical significance of multidrug resistence p-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473–476
Catovsky D, Matutes E, Buccheri V, Shetty V, Hanslip J, Yoshida N, Morilla R (1991) A classification of acute leukemia for the 1990s. Ann Hematol 62:16–21
Lee EJ, Pollak A, Leavitt RD, Testa JR, Schiffer CA (1987) Minimally differentiated acute lymphocytic leukaemia: a distinct entity. Blood 70:1400–1406
Sempere A, Jarque 1, Guinot M, Palau J, García R, Sanz GF, Gomis F, Pérez-Sirvent ML, Senent L, Sanz MA (1993) Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases. Leukemia Lymphoma 12:103–108
Stasi R, Del Poeta G, Venditti A, Masi M, Stipa E, Dentamaro T, Cox C, Dallapiccola B, Papa G (1994) Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood 83:1619–1625
Stone RM, Mayer RJ (1993) Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. In: Bloomfield CD, Herzig GP (eds) Hematology/oncology clinics of North America, management of acute leukemia. WB Saunders, Philadelphia, pp 47–64
Veer MB van't, Kluin-Nelemans JC, Schoot CE van der, Putten WLJ van, Adriaansen HJ, Wering ER van (1992) Quality assessment of immunological marker analysis and the immunological diagnosis in leukaemia and lymphoma: a multi-centre study. Br J Haematol 80:458–465
Visser JWM, Bekkum DW van (1990) Purification of pluripotent hematopoietic stem cells: past and present. Exp Hematol 18:248–256
Yokose N, Ogata K, Ito T, Miyake K, An E, Inokuchi K, Yamada T, Gomi S, Tanabe Y, Ohki I, Kuwabara T, Hasegawa S, Shinohara T, Dan K, Nomura T (1993) Chemotherapy for minimally differentiated acute myeloid leukemia (AML-M0). Ann Hematol 66:67–70
Author information
Authors and Affiliations
Additional information
The following persons participated in the Dutch Slide Review Committee of Adult Leukemias: J. van der Lelie, Academical Medical Center, Amsterdam; M. M. A. C. Langenhuijsen, Free Academical University Hospital, Amsterdam; S. M. G. J. Daenen, University Hospital, Groningen; J. C. Kluin-Nelemans, University Hospital Leiden; G. J. den Ottolander, University Hospital Leiden; G. E. G. Verhoef, Gasthuisberg, Leuven, Belgium; M. A. ten Haaft, University Hospital, Maastricht; R. S. G. Holdrinet, University Hospital Nijmegen; H. Mallios, University Hospital Rotterdam; G. E. de Greef, Dr. Daniel den Hoed Cancer Center, Rotterdam; M. B. van 't Veer, Dr. Daniel den Hoed Cancer Center, Rotterdam; H. M. Lokhorst, University Hospital, Utrecht, The Netherlands.
Rights and permissions
About this article
Cite this article
Segeren, C.M., de Jong-Gerrits, G.C.M.M. & van't Veer, M.B. AML-M0: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients. Ann Hematol 70, 297–300 (1995). https://doi.org/10.1007/BF01696615
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01696615